Due to the lack of available data, we could not compare the differences in the efficacy of anti-CTLA-4 monotherapy and combination therapy involving both anti-CTLA-4 anti-PD-1 in patients with MAP2K1/2-mutated melanoma in this study. Here, MAP2K1 is linked to melanoma.